Download PDF
Pharmacopsychiatry 2000; 33(3): 89-97
DOI: 10.1055/s-2000-7978
Original Paper
Georg Thieme Verlag Stuttgart · New York

Cyclandelate in the Treatment of Patients with Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Vascular Dementia: Experience from a Placebo Controlled Multi-center Study

G. Weyer1 , A. Eul2 , K. Milde2 , W. Wierich3 , W. M. Herrmann4
  • 1Institute of Psychology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany
  • 23M Medica, Borken (Westfalen), Germany
  • 3Parexel GmbH, Berlin, Germany
  • 4Department of Psychiatry, Benjamin Franklin Hospital, Free University of Berlin, Germany
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

A 24-week, double-blind, multi-center, randomised parallel group study compared the efficacy and safety of 800 mg bid cyclandelate with placebo in patients with mild to moderate dementia of primary degenerative or vascular origin. A total of 196 patients entered the study, 147 patients completed treatment in adherence with the protocol. Primary outcome measures were the cognitive score of the Alzheimer's Disease Assessment Scale (ADAS-Cog), the subscale Instrumental Activities of Daily Living of the Nurses' Observation Scale for Geriatric Patients (NOSGER-IADL) and the Clinical Global Impressions of Change (CGI-C). Safety assessments included adverse events, vital signs, ECG and clinical laboratory parameters. The primary efficacy results based on a multi-level responder analysis including ADAS-Cog, NOSGER-IADL and CGI-C failed to demonstrate statistical superiority of cyclandelate in comparison to placebo. The direction of changes favored cyclandelate in each of the variables, but the differences to placebo were small and varied considerably between patients and centers. Retrospective exploratory analyses suggested that efficacy of cyclandelate might be dependent on the severity of the disease. The treatment effects in favor of cyclandelate were statistically significant in the subgroup of moderately impaired patients (MMSE at baseline < 18) for ADAS-Cog (Ä = − 4.0 points, p = 0.015) and CGI-C (Ä = − 0.4 points, p = 0.043) but not for NOSGER-IADL (Ä = − 1.6 points, p = 0.059). When patients were stepwise selected for the severity of the disease according to ADAS-Cog at baseline (> 15, > 20, > 25 points), statistical significance was reached for ADAS-Cog and NOSGER-IADL beginning with the step ADAS-Cog > 20 points: Ä ADAS-Cog = − 3.9 points, p = 0.044; Ä NOSGER-IADL = -1.0, p = 0.023. The treatment differences increased further with the step ADAS-Cog > 25 points: Ä ADAS-Cog = − 7.0 points, p = 0.008; Ä NOSGER-IADL = − 1.7, p = 0.003. Treatment differences in CGI-C increased marginally with the stepwise selection but did not reach statistical significance. The drug was safe and well tolerated.

References

  • 1  American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-Revised. (3rd ed.). Washington, DC: Author 1987
    Google Scholar
  • 2 Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with exelon (ENA-713) in Alzheimer's disease: An overview.  Journal of Drug Development and Clinical Practice. 1996;  8 109-116
    PubMedGoogle Scholar
  • 3 Bijlsma U G, Funcke A BH, Tersteege H M, Rekker R F, Ernsting M JE, Nauta W Th. The pharmacology of cyclospasmol.  Archives Internationales de Pharmacodynamie et de Therapie.. 1956;  105 145-174
    PubMedGoogle Scholar
  • 4 Blakemore C B. The clinical efficacy of cyclospasmol: a review of the literature.  British Journal of Clinical Practice.. 1984;  38 3-7
    PubMedGoogle Scholar
  • 5 Bodick N C. et al . Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease.  Archives of Neurology.. 1997;  54 465-473
    PubMedGoogle Scholar
  • 6  CPMP, Committee for Proprietary Medicinal Products. Note for guidance on medicinal products in the treatment of Alzheimer's disease. London: The European Agency for the Evaluation of Medicinal Products. 1997
    Google Scholar
  • 7 Fischhof P K, Rüther E, Wagner G, Litschauer G. Therapieergebnisse mit Nimodipin bei primär degenerativer Demenz und Multiinfarktdemenz.  Zeitschrift für Geriatrie. 1990;  6 320-327
    PubMedGoogle Scholar
  • 8 Fischhof P K. et al . The therapeutic efficacy of vincamine in dementia.  Neuropsychobiology.. 1996;  34 29-35
    PubMedGoogle Scholar
  • 9 Folstein M F, Folstein S E, McHugh P R. “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician.  Journal of Psychiatric Research. 1975;  12 189-198
    CrossrefPubMedGoogle Scholar
  • 10 Herrmann W M, Stephan K. Efficacy and clinical relevance of cognition enhancers.  Alzheimer Disease and Associated Disorders.. 1991;  5 (Suppl. 1) -12
    PubMedGoogle Scholar
  • 11 Ihl R, Frölich L, Dierks T, Martin E-A, Maurer K. Differential validity of psychometric tests in dementia of the Alzheimer type.  Psychiatry Research.. 1992;  44 93-106
    CrossrefPubMedGoogle Scholar
  • 12 Jacobson N S, Truax P. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research.  Journal of Consulting and Clinical Psychology. 1991;  59 12-19
    CrossrefPubMedGoogle Scholar
  • 13 Kanowski S, Herrmann W M, Stephan K, Wierich W, Hörr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate dementia of the Alzheimer type or multi-infarct demtia.  Pharmacopsychiatry. 1996;  29 47-56
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kanowski S, Ladurner G, Maurer K, Oswald W D, Stein U. Empfehlungen zur Evaluierung der Wirksamkeit von Nootropika.  Zeitschrift für Gerontopsychologie und -psychiatrie. 1990;  3 67-79
    PubMedGoogle Scholar
  • 15 Kapoula O. et al .Placebo-kontrollierte Doppelblind-Studie zur Prüfung der therapeutischen Wirksamkeit von Cyclandelat bei ambulanten Patienten mit vaskulär bedingten Hirnleistungsstörungen im Alter. (unpublished manuscript).
    Google Scholar
  • 16 Kern U, Menges K. Proof of efficacy of nootropics for the indication ‘dementia’ (Phase III) - Recommendations.  Pharmacopsychiatry. 1992;  25 126-135
    PubMedGoogle Scholar
  • 17 Knapp M J, Gracon St. I, Davis C S, Solomon P R, Pendlebury W W, Knopman D S. Efficacy and safety of high-dose tacrine: A 30-week evaluation.  Alzheimer Disease and Related Disorders. 1994;  8 (Supl. 2) -31
    PubMedGoogle Scholar
  • 18 Lienert G A. Testaufbau und Testanalyse (2nd. ed.) [Test construction and test analysis]. Weinheim, Germany: Beltz. 1967
    Google Scholar
  • 19 Marcusson J. et al . A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R.  Dementia and Geriatric Cognitive Disorders. 1997;  8 320-328
    PubMedGoogle Scholar
  • 20 Möller H J. Dementia treatment: a German perspective on psychosocial aspects and therapeutic approaches.  International Psychogeriatrics.. 1995;  7 459-470
    CrossrefPubMedGoogle Scholar
  • 21 Montgomery S A, Asberg M. A new depression rating scale designed to be sensitive to change.  British Journal of Psychiatry.. 1975;  134 382-389
    PubMedGoogle Scholar
  • 22 Morich F J. et al . Nimodipine in the treatment of probable Alzheimer's disease. Results of two multicentre trials.  Clinical Drug Investigation.. 1996;  11 185-195
    PubMedGoogle Scholar
  • 23  National Institute of Mental Health. Clinical Global Impressions. In W. Guy (Ed.), EDCEU assessment manual for psychopharmacology, Rev, ed. Rockville, MD: Author 1976: 217-222
    Google Scholar
  • 24 Rogers S L, Friedhoff L T. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomised, placebo-controlled trial.  Dementia. 1996;  7 293-303
    PubMedGoogle Scholar
  • 25 Rosen W G, Mohs R S, Davis K L. A new rating scale for Alzheimer's disease.  American Journal of Psychiatry.. 1984;  141 1356-1364
    CrossrefPubMedGoogle Scholar
  • 26 Rosen W G, Terry R D, Fuld P A, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias.  Annals of Neurology.. 1980;  7 486-488
    CrossrefPubMedGoogle Scholar
  • 27 Saletu B. et al . Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study.  Psychopharmacology.. 1995;  117 385-395
    PubMedGoogle Scholar
  • 28 Schellenberg R, Todorova A, Dimpfel W, Schober F. Pathophysiology and psychopharmacology of dementia - A new study design, part I: diagnosis comprising subjective and objective criteria.  Neuropsychobiology. 1995;  32 81-97
    PubMedGoogle Scholar
  • 29 Schellenberg R, Todorova A, Wedekind W, Schober F, Dimpfel W. Pathophysiology and psychopharmacology of dementia - A new study design, part II: cyclandelate treatment - A placebo-controlled, double-blind clinical trial.  Neuropsychobiology. 1997;  35 132-142
    PubMedGoogle Scholar
  • 30 Spiegel R, Brunner C, Ermini-Fünfschilling D, Monsch A, Notter M, Puxty J, Tremmel L. A new behavioral assessment scale for geriatric out- and in-patients: The NOSGER (Nurses' Observation Scale for Geriatric Patients).  Journal of the American Geriatrics Society.. 1991;  39 339-347
    PubMedGoogle Scholar
  • 31 Stöcker G. et al .Assessment in cerebrovascular insuffiency. An international symposium on various methods of assessing the effect of cyclandelate on higher cortical function. Würzburg, Stuttgart, Germany: Thieme. 1970
    Google Scholar
  • 32 Thal L J. et al . A multi-centre double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease.  Neurology. 1996;  47 1389-1395
    PubMedGoogle Scholar
  • 33 Weyer G. Methodologische Überlegungungen zur Bestimmung von Therapierespondern in Nootropikastudien [Methodological considerations on defining responders to therapy in nootropic drug studies]. In J. Oldigs-Kerber & J.P. Leonard (Eds.), Pharmakopsychologie: Experimentelle und klinische Aspekte. Jena, Germany: G. Fischer. 1992: 380-393
    Google Scholar
  • 34 Weyer G, Ihl R, Schambach. Alzheimer's Disease Assessment Scale (ADAS ). Deutschsprachige Bearbeitung. Dokumentationsbogen und Testmaterial. Weinheim, Germany: Beltz Test. 1992
    Google Scholar
  • 35 Weyer G, Erzigkeit H, Hadler D, Kubicki S. Efficacy and safety of idebenone in the long-term treatment of Alzheimer's disease: A double-blind, placebo-controlled multicentre study.  Human Psychopharmacology Clinical and Experimental.. 1996;  11 53-65
    CrossrefPubMedGoogle Scholar
  • 36 Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D. Alzheimer's Disease Assessment Scale: Reliability and validity in a multicenter clinical trial.  International Psychogeriatrics.. 1997 a;  9 123-138
    PubMedGoogle Scholar
  • 37 Weyer G, Babej-Dölle R M, Hadler D, Hofmann S, Herrmann W M. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.  Neuropsychobiology.. 1997 b;  36 73-82
    PubMedGoogle Scholar
  • 38 Zaudig M, Mittelhammer J, Hiller W. SIDAM-Strukturiertes Interview für die Diagnose der Demenz vom Alzheimer-Typ, Multiinfarktdemenz und Demenzen anderer Ätiologie nach DSM-III-R und ICD-10. München: Logomed. 1990
    Google Scholar
  • 39 Zec R F, Landreth E S, Vicari S K, Feldman E, Belman J, Andrise A, Robbs R, Kumar V, Becker R V. Alzheimer Disease Assessment Scale: Useful for both early detection and staging of dementia of the Alzheimer type.  Alzheimer Disease and Associated Disorders.. 1992;  6 89-102
    PubMedGoogle Scholar

Prof. Dr. Geerd Weyer

Independent Clinical Research Consultant

Herbergerweg 10

D-14167 Berlin

Germany

      >